Eton Pharmaceuticals has been granted a patent for oral liquid formulations of hydrocortisone for treating various diseases. The composition includes hydrocortisone, glycerin, and other carriers, with less than 5% water content. GlobalData’s report on Eton Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Eton Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Eton Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Eton Pharmaceuticals's grant share as of February 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11904046B1) discloses a liquid pharmaceutical composition containing hydrocortisone or its salt in a nonaqueous liquid carrier, primarily comprising glycerin. The composition, designed as an oral solution, contains less than 5% water and is stable for at least 3 months at room temperature. The formulation also includes propylene glycol, polyethylene glycol (PEG), or alcohol in varying amounts, with glycerin constituting 40% to 80% of the composition. Additionally, the composition may contain preservatives, flavoring agents, and sweeteners to enhance palatability and efficacy.

Furthermore, the patent covers a method of treating various diseases or conditions by administering the disclosed liquid pharmaceutical composition, particularly targeting inflammation and adrenal insufficiency. The composition's stability, low water content, and specific ingredient proportions make it suitable for treating a range of ailments, including endocrine disorders, rheumatic disorders, dermatologic diseases, and more. The patent also includes provisions for a kit enclosing the liquid pharmaceutical composition, ensuring convenient and effective delivery for patients in need of the specified treatments. Overall, the patent highlights a novel formulation with precise ingredient ratios and stability parameters, offering a promising solution for treating a diverse array of medical conditions.

To know more about GlobalData’s detailed insights on Eton Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies